CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.
CHU de Lille, Service de Pneumologie et Immuno-allergologie, Centre de référence constitutif pour les maladies pulmonaires rares, Univ. Lille, Lille, France.
Chest. 2021 Mar;159(3):e131-e135. doi: 10.1016/j.chest.2020.10.003.
Emphysema is a chronic respiratory disorder characterized by destruction of alveoli, usually due to cigarette smoking or exposure to noxious particles or gases. Dysfunction of proteins that are involved in lung development and maintenance, such as alpha-1 antitrypsin, also contributes to emphysema. Filamin A (FLNA) is an actin-binding protein involved in cytoskeleton reorganization. Mutations in the FLNA gene classically lead to abnormal neuronal migration and connective and vascular tissue anomalies. Pulmonary manifestations consist of a wide range of pulmonary disorders that occur during infancy. We report the first familial case of emphysema in non- and very low-smoking adults who carry a loss-of-function mutation of the FLNA gene. The identification of this new risk factor for emphysema encourages (1) screening, prevention and monitoring of pulmonary disorders in patients with FLNA mutation and (2) screening for FLNA mutation in patients with early-onset emphysema that is associated with low-smoking or vascular or connective tissue anomalies.
肺气肿是一种慢性呼吸系统疾病,其特征是肺泡破坏,通常由于吸烟或暴露于有害颗粒或气体所致。参与肺发育和维持的蛋白质(如α-1抗胰蛋白酶)的功能障碍也会导致肺气肿。细丝蛋白 A(FLNA)是一种参与细胞骨架重组的肌动蛋白结合蛋白。FLNA 基因突变通常导致神经元迁移异常以及结缔组织和血管组织异常。肺部表现包括在婴儿期发生的一系列广泛的肺部疾病。我们报告了首例非吸烟和极低吸烟的成年肺气肿家族病例,这些患者携带 FLNA 基因突变导致其功能丧失。确定这种肺气肿的新危险因素,鼓励(1)对携带 FLNA 基因突变的患者进行肺部疾病的筛查、预防和监测,以及(2)对与低吸烟或血管或结缔组织异常相关的早发性肺气肿患者进行 FLNA 基因突变筛查。